Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care.

Cell Rep 2017 Dec;21(11):3298-3309

Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA. Electronic address:

Personalized cancer therapy is based on a patient's tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis. Here, we aim to develop an in vitro functional assay of a patient's living cancer cells that could complement these approaches. We present methods for developing cell cultures from tumor biopsies and identify the types of samples and culture conditions associated with higher efficiency of model establishment. Toward the application of patient-derived cell cultures for personalized care, we established an immunofluorescence-based functional assay that quantifies cancer cell responses to targeted therapy in mixed cell cultures. Assaying patient-derived lung cancer cultures with this method showed promise in modeling patient response for diagnostic use. This platform should allow for the development of co-clinical trial studies to prospectively test the value of drug profiling on tumor-biopsy-derived cultures to direct patient care.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.11.051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745232PMC
December 2017
47 Reads

Publication Analysis

Top Keywords

cell cultures
12
functional assay
8
personalized cancer
8
cancer cells
8
patient care
8
cancer
6
cultures
5
culture conditions
4
samples culture
4
platform allow
4
types samples
4
diagnostic platform
4
conditions associated
4
response diagnostic
4
associated higher
4
efficiency model
4
identify types
4
higher efficiency
4
biopsies identify
4
developing cell
4

Similar Publications